vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and EXPONENT INC (EXPO). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $166.3M, roughly 1.6× EXPONENT INC). EXPONENT INC runs the higher net margin — 17.8% vs 1.4%, a 16.4% gap on every dollar of revenue. On growth, EXPONENT INC posted the faster year-over-year revenue change (14.3% vs 9.7%). Over the past eight quarters, EXPONENT INC's revenue compounded faster (8.8% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Exponent, Inc. is an American engineering and scientific consulting firm. Exponent has a team of scientists, physicians, engineers, and business consultants which performs research and analysis in more than 90 technical disciplines. The company operates 20 offices in the United States and five offices overseas.
ACAD vs EXPO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $166.3M |
| Net Profit | $3.6M | $29.6M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | 24.9% |
| Net Margin | 1.4% | 17.8% |
| Revenue YoY | 9.7% | 14.3% |
| Net Profit YoY | — | 11.0% |
| EPS (diluted) | $0.02 | $0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $166.3M | ||
| Q4 25 | $284.0M | $147.1M | ||
| Q3 25 | $278.6M | $142.0M | ||
| Q2 25 | $264.6M | $145.5M | ||
| Q1 25 | $244.3M | $136.8M | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | $136.3M | ||
| Q2 24 | $242.0M | $140.5M |
| Q1 26 | $3.6M | $29.6M | ||
| Q4 25 | $273.6M | $28.0M | ||
| Q3 25 | $71.8M | $26.6M | ||
| Q2 25 | $26.7M | $26.6M | ||
| Q1 25 | $19.0M | $23.6M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $26.0M | ||
| Q2 24 | $33.4M | $29.2M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | 24.9% | ||
| Q4 25 | 6.1% | 19.7% | ||
| Q3 25 | 12.8% | 12.1% | ||
| Q2 25 | 12.2% | 30.5% | ||
| Q1 25 | 7.9% | 19.9% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 19.0% | ||
| Q2 24 | 12.6% | 25.4% |
| Q1 26 | 1.4% | 17.8% | ||
| Q4 25 | 96.3% | 19.1% | ||
| Q3 25 | 25.8% | 18.7% | ||
| Q2 25 | 10.1% | 18.3% | ||
| Q1 25 | 7.8% | 17.2% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 19.1% | ||
| Q2 24 | 13.8% | 20.8% |
| Q1 26 | $0.02 | $0.59 | ||
| Q4 25 | $1.61 | $0.55 | ||
| Q3 25 | $0.42 | $0.52 | ||
| Q2 25 | $0.16 | $0.52 | ||
| Q1 25 | $0.11 | $0.45 | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $0.50 | ||
| Q2 24 | $0.20 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $118.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $338.3M |
| Total Assets | $1.6B | $687.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $118.6M | ||
| Q4 25 | $177.7M | $207.4M | ||
| Q3 25 | $258.0M | $231.8M | ||
| Q2 25 | $253.6M | $245.1M | ||
| Q1 25 | $217.7M | $258.9M | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | $219.7M | ||
| Q2 24 | $177.1M | $203.3M |
| Q1 26 | — | $338.3M | ||
| Q4 25 | $1.2B | $402.9M | ||
| Q3 25 | $917.3M | $427.8M | ||
| Q2 25 | $822.4M | $441.4M | ||
| Q1 25 | $765.2M | $421.1M | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | $410.3M | ||
| Q2 24 | $516.7M | $393.2M |
| Q1 26 | $1.6B | $687.4M | ||
| Q4 25 | $1.6B | $761.4M | ||
| Q3 25 | $1.3B | $759.4M | ||
| Q2 25 | $1.2B | $763.2M | ||
| Q1 25 | $1.1B | $777.3M | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | $744.1M | ||
| Q2 24 | $914.1M | $709.2M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
Segment breakdown not available.
EXPO
| Revenues before reimbursements | $151.8M | 91% |
| Reimbursements | $14.5M | 9% |
